RESUMO
We evaluated a new protocol for the BacT/ALERT MB susceptibility test (bioMérieux Inc., Durham, NC) using 80 Mycobacterium tuberculosis WHO challenge panel strains. The drug susceptibility profiles of these strains are well characterized, and consensus drug resistance results have been established after tests were performed at around 20 international reference laboratories using recommended reference drug susceptibility techniques. Strains were tested according to the bioMérieux protocol using the following critical concentrations: rifampin (RIF), 0.9 mg/liter; isoniazid (INH), 0.4 and 0.09 mg/liter; and ethambutol (EMB), 1.8 mg/liter. The BacT/ALERT system detected 36/37 RIF-resistant strains. For INH (low concentration), 59/59 resistant strains were detected, and for EMB, 34/34 resistant strains were detected. Thus, the sensitivities were 97%, 100%, and 100% for RIF, INH, and EMB, respectively. The corresponding specificities were 100%, 95%, and 98%, respectively, for the same drugs. As soon as the BacT/ALERT MP seed bottle flagged positive, the median time to obtain a susceptibility results was 7.8 days. The results show good concordance with the consensus results of the international reference laboratories and demonstrate that BacT/ALERT 3D should be considered as an alternative method for rapid and automated drug susceptibility testing of M. tuberculosis.
Assuntos
Antituberculosos/farmacologia , Mycobacterium tuberculosis/efeitos dos fármacos , Kit de Reagentes para Diagnóstico , Técnicas Bacteriológicas , Meios de Cultura , Farmacorresistência Bacteriana , Etambutol/farmacologia , Humanos , Isoniazida/farmacologia , Testes de Sensibilidade Microbiana/instrumentação , Testes de Sensibilidade Microbiana/normas , Mycobacterium tuberculosis/crescimento & desenvolvimento , Padrões de Referência , Rifampina/farmacologia , Sensibilidade e EspecificidadeRESUMO
Multidrug-resistant tuberculosis is an increasing public health concern in many parts of the world, especially in low-income countries, where most cases occur. Traditional drug susceptibility testing is either time-consuming, such as the proportion method on solid media, or expensive, such as the BACTEC 460 system. We have evaluated a new nitrate reductase assay (NRA) that depends on the ability of Mycobacterium tuberculosis to reduce nitrate to nitrite. The reduction can be detected using specific reagents, which produce a color change. We tested a panel of 57 M. tuberculosis strains with various resistance patterns. The bacteria were inoculated on Löwenstein-Jensen medium, either without drugs or with rifampin, isoniazid, streptomycin, or ethambutol and with potassium nitrate (KNO(3)) incorporated. After incubation for 7, 10, or 14 days, the reagents were added and nitrate reduction, indicating growth, could be detected by a color change. Sensitivities to and specificities for drugs as determined by the NRA method compared to those determined by the BACTEC 460 method were 100 and 100% for rifampin, 97 and 96% for isoniazid, 95 and 83% for streptomycin, and 75 and 98% for ethambutol, respectively. The results were in the majority of the cases available in 7 days. The evaluated method is rapid and inexpensive and could correctly identify most resistant and sensitive M. tuberculosis strains. It has the potential to become an interesting alternative to existing methods, such as the proportion and BACTEC methods, particularly in resource-poor settings.
Assuntos
Antituberculosos/farmacologia , Mycobacterium tuberculosis/efeitos dos fármacos , Nitrato Redutases/metabolismo , Humanos , Testes de Sensibilidade Microbiana/métodos , Mycobacterium tuberculosis/enzimologia , Mycobacterium tuberculosis/genética , Nitrato Redutase , Nitratos/metabolismo , Oxirredução , Sensibilidade e Especificidade , Fatores de Tempo , Tuberculose/microbiologiaRESUMO
OBJECTIVE: To investigate the use of DNA amplification by the polymerase chain reaction (PCR) for the detection of Mycobacterium tuberculosis directly in human respiratory specimens. METHODS: The PCR assay employed was the Amplicor M. tuberculosis Test (Roche Diagnostics, Switzerland), which uses the 16S rDNA as the target template. Nine hundred and sixty samples from 741 patients in two clinical microbiology laboratories in Norway and Sweden were processed by routine culture analysis and PCR. RESULTS: Of the 56 specimens containing cultivatable M. tuberculosis, 49 (87.5%) were detected by PCR. Among the 904 culture-negative specimens, 897 samples were negative also by PCR and seven (0.8%) were positive by PCR. In comparison with culture, the sensitivity, specificity, and positive and negative predictive values of PCR were 91.7%, 99.6%, 94.2% and 99.4% for laboratory 1 and 80.0%, 98.7%, 76.2% and 99.0% for laboratory 2, respectively. For both laboratories combined the values were 87.5%, 99.2%, 87.5% and 99.2%. CONCLUSIONS: These results indicate that multiple (two or three) respiratory samples from each patients should be tested, to allow sufficient accuracy in detecting M. tuberculosis in the specimens. Still, the labor-intensive format of this test necessitates strong clinical indications and patient prioritization to provide a service feasible within the current limits of routine laboratories.